Replidyne, Inc. to Announce Second Quarter 2007 Earnings

LOUISVILLE, Colo., July 10 /PRNewswire-FirstCall/ -- Replidyne, Inc. announced today that it will host a conference call and webcast on Tuesday, July 31, 2007 at 4:45 P.M. ET to report second quarter 2007 earnings.

Callers may participate in the conference call by dialing 888-680-0890 (domestic) or 617-213-4857 (international), and providing the passcode 27796470. If you wish to pre-register for the conference call, you may do so on the Investor Relations section of the company’s website, http://www.Replidyne.com. A live webcast will also be available at this location.

A replay of the conference call will be available approximately one hour after completion of the call through Tuesday, August 14, 2007 at midnight. Callers may access the replay by dialing 888-286-8010 (U.S. participants) or 617-801-6888 (international participants). The audio replay passcode is 31540010. To access a replay of the webcast, visit the Investor Relations section of the company’s website at http://www.Replidyne.com.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne’s lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne’s second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne is also pursuing the development of other novel anti-infective products based on its in-house discovery research.

Replidyne, Inc.

CONTACT: Sabrina B. Oei, Dir., Investor & Public Relations of Replidyne,Inc., +1-303-996-5535

MORE ON THIS TOPIC